The Indian biotech industry consists of some of the popular biotech stocks in India. Being a major hub for biotech research, it is an attractive option for those looking to invest in biotech stocks. Let’s see some key points to understand the Indian biotech sector:
- In 2022, the Indian biotech industry surpassed US $80.12 billion. This surge marked a 14% increase from the previous year.
- The industry aims to grow significantly with a target of US $150 billion by 2025 and US $300 billion by 2030.
- India is one of the largest suppliers of low-cost drugs globally. Currently, we are exporting medicines to over 150 countries.
- India is the 7th largest destination in the world for conducting affordable clinical trials.
Now, let’s have a look at some of biotechnology stocks in India (data as of August 5, 2024):
Company name
|
Market capitalisation
|
Dr. Reddy’s Labortories
|
Rs. 1,16,182 crore
|
Syngene International
|
Rs. 33,038.22 crore
|
Biocon
|
Rs. 42,753.37 crore
|
Sun Pharma Advanced Research
|
Rs. 7,341.98 crore
|
Wockhardt Ltd.
|
Rs. 13,797.65 crore
|
Dr. Reddy's Laboratories
It is the largest biotech company in India in terms of market capitalisation. Primarily, the company operates in the “Global Generics” segment. It produces and markets both prescription and over-the-counter drugs. Currently, Dr. Reddy has a portfolio of over 190 medicines and 60 active pharmaceutical ingredients (APIs). Moreover, the company's reach is extensive. Around 80% of its revenue is generated from international markets.
Syngene International
Syngene International is an Indian biotech company. It specialises in the early discovery and commercial manufacturing of large molecules. It offers integrated research and development (R&D) and manufacturing services for a wide range of sectors, such as pharmaceuticals, speciality chemicals, biotechnology, consumer goods, nutrition, and animal health. Moreover, its comprehensive capabilities support its clients in developing innovative solutions from initial discovery through to commercial production.
Biocon
Biocon focuses on creating novel drugs. The company specifically addresses diseases such as diabetes, cancer, and immune disorders. Some of its common business segments are generics, biosimilars, novel biologics, and research services.
Also, Biocon is committed to improving health outcomes across 120 countries. This way, the company is making significant strides in enhancing global healthcare through its innovative drug development and widespread reach.
Sun Pharma advanced research
Sun Pharma Advanced Research is the fourth largest generic pharmaceutical company globally. It boasts a revenue of US $5.1 billion. The company has facilities to undertake extensive research and develop complex pharmaceutical products, particularly in oncology, neurodegeneration, and immunology. Sun Pharma also has 40 state-of-the-art manufacturing facilities with a client base across 100 countries.
Wockhardt Ltd.
Wockhardt Ltd. is engaged in the manufacturing of pharmaceutical and bio-pharmaceutical formulations. It produces medicines for various therapeutic areas, including dermatology, osteoarthritis, cosmeceuticals, medical nutrition, and oncology. The company has comprehensive biotechnology capabilities. It includes gene cloning, development of production strains, purification, downstream processing, and market formulation. This way, Wockhardt delivers high-quality pharmaceutical solutions using its modern technologies and expertise.